UMB Bank’s Legend Biotech LEGN Stock Holding History

UMB Bank’s Portfolio LEGN Stock Details LEGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-331	Closed	-$15K	–	2031
2021 Q4	$15K	Buy	+331	New	+$16.8K	﹤0.01%	1344

Other funds holding LEGN

HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return

UMB Bank's LEGN Position: Q1 2022 in Review

UMB Bank sold out of Legend Biotech (LEGN) in Q1 2022, closing a stake of 331 shares — an estimated $15K sold.

UMB Bank first reported a position in LEGN in Q4 2021 and held it in 1 quarter. The position peaked at $15K in Q4 2021. 141 funds tracked by Wall St. Rank hold LEGN as of Q1 2022.

UMB Bank reported no remaining Legend Biotech position as of Q1 2022 after selling out during the quarter.
UMB Bank sold 331 Legend Biotech shares in Q1 2022, an estimated $15K.
UMB Bank first reported a position in Legend Biotech in Q4 2021 and held it in 1 quarter.
UMB Bank's Legend Biotech position peaked at $15K in Q4 2021.
141 funds tracked by Wall St. Rank held Legend Biotech as of Q1 2022.

Based on UMB Bank's 13F filing for Q1 2022, filed 22 Apr 2022.